Skip to main content
main-content

The American Diabetes Association | Virtual Scientific Sessions

12 JUNE – 16 JUNE

Top stories

Expert interviews

06-24-2020 | ADA 2020 | Conference coverage | Article

ADA 2020 goes virtual! Editorial Board conference highlights

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

06-23-2020 | ADA 2020 | Podcast | Article

Expert commentary: Closed-loop insulin delivery research update

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

06-18-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: The VERTIS-CV trial

Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).

06-16-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: The VERTIS-CV trial

Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).

06-15-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: Putting telehealth into practice for type 2 diabetes

Matthew Crowley discusses the successful implementation of a telehealth service for rural people with type 2 diabetes in clinical practice and its relevance to the current pandemic (13:07).

06-16-2020 | ADA 2020 | Conference coverage

Expert commentary: Could SGLT2 inhibition protect the liver in type 2 diabetes?

John Wilding discusses preliminary evidence that SGLT2 inhibition may counteract the adverse effects of type 2 diabetes on the liver (3:10).

06-14-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: Icosapent ethyl lowers cardiovascular risk in people with diabetes

Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).

Latest research news

06-24-2020 | ADA 2020 | Conference coverage | News

More studies show potential for slowing type 1 diabetes progression

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

06-23-2020 | ADA 2020 | Conference coverage | News

​​​​​​​CGM predictive low glucose alerts may prevent rebound hyperglycemia

Predictive low glucose alerts are associated with a reduced frequency and severity of rebound hyperglycemia among people using real-time continuous glucose monitoring, show study findings presented at the virtual ADA 80th Scientific Sessions.

06-17-2020 | ADA 2020 | Conference coverage | News

​​​​​​​Support for insulin degludec use in type 1 diabetes patients prone to nocturnal hypoglycemia

Findings from the HypoDeg trial suggest that insulin degludec is associated with a lower risk for hypoglycemia than insulin glargine U100 among people with type 1 diabetes who are prone to nocturnal severe hypoglycemia.

06-16-2020 | ADA 2020 | Conference coverage | News

Dapagliflozin may help prevent type 2 diabetes

06-15-2020 | ADA 2020 | Conference coverage | News

Evidence for liver benefits with SGLT2 inhibition


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Virtual EASD Annual Meeting 2020 coverage

Get the latest news and expert commentary now.

Image Credits